Spotlight on Atomoxetine in Attention-Deficit Hyperactivity Disorder in Children and Adolescents†
The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Atomoxetine (Strattera) is a selective noradrenaline (norepinephrine) reuptake inhibitor that is not classified as a stimulant, and is indicated for use in patients with attention-deficit hyperactivity disorder (ADHD). Atomoxetine is effective and generally well tolerated. It is significantly more effective than placebo and standard current therapy and does not differ significantly from, or is noninferior to, immediate-release methylphenidate; however, it is significantly less effective than the extended-release methylphenidate formulation OROS methylphenidate (hereafter referred to as osmotically released methylphenidate) and extended-release mixed amfetamine salts. Atomoxetine can be administered either as a single daily dose or split into two evenly divided doses, has a negligible risk of abuse or misuse and is not a controlled substance in the US. Atomoxetine is particularly useful for patients at risk of substance abuse, as well as those who have co-morbid anxiety or tics, or who do not wish to take a controlled substance. Thus, atomoxetine is a useful option in the treatment of ADHD in children and adolescents.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Even though several classes of medications are available to manage ADHD (e.g. stimulants such as methylphenidates and amphetamines; and non-stimulant medications such as atomoxetine, guanfacine and clonidine), intake of these medications are commonly associated with adverse effects ranging from loss of appetite, and irritability to suicidal ideation18,19 and therefore are not well-tolerated20.”
From Effects of l-theanine–caffeine combination on sustained attention and inhibitory control among children with ADHD: a proof-of-concept neuroimaging RCT (2020) · cites this paper as [19]
In the citing paper
“abnormalities in DA and NE signalling have been reported in both MDD and ADHD, suggesting a potentially shared underlying pathophysiology, at least in some individuals [56][57][58][59].”
From Adult ADHD and comorbid disorders: clinical implications of a dimensional approach (2017) · cites this paper as [57]
Citations
Cites
Bymaster, F. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00346-9 · Cited by 1,123
Michelson, D., Faries, D., Wernicke, J., Kelsey, D., Kendrick, K., Sallee, F. R., Spencer, T., & the Atomoxetine ADHD Study Group (2001) · Pediatrics · doi:10.1542/peds.108.5.e83 · Cited by 666
Michelson, D., Allen, A. J., Busner, J., Casat, C., Dunn, D., Kratochvil, C., Newcorn, J., Sallee, F. R., Sangal, R. B., Saylor, K., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.11.1896 · Cited by 599
Kelsey, D. K., Sumner, C. R., Casat, C. D., Coury, D. L., Quintana, H., Saylor, K. E., Sutton, V. K., Gonzales, J., Malcolm, S. K., Schuh, K. J., et al. (2004) · Pediatrics · doi:10.1542/peds.114.1.e1 · Cited by 464
Garnock-Jones, K. P., & Keating, G. M. (2009) · Pediatric Drugs · doi:10.2165/00148581-200911030-00005 · Cited by 392
Self-citationBlockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes
Bolden-Watson, C., & Richelson, E. (1993) · Life Sciences · doi:10.1016/0024-3205(93)90194-8 · Cited by 390
Binding of antidepressants to human brain receptors: focus on newer generation compounds
Cusack, B., Nelson, A., & Richelson, E. (1994) · Psychopharmacology · doi:10.1007/bf02244985 · Cited by 349
Newcorn, J. H., Kratochvil, C. J., Allen, A. J., Casat, C. D., Ruff, D. D., Moore, R. J., Michelson, D., & Atomoxetine/Methylphenidate Comparative Study Group (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.05091676 · Cited by 336
Spencer, T., Heiligenstein, J. H., Biederman, J., Faries, D. E., Kratochvil, C. J., Conners, C. K., & Potter, W. Z. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1209 · Cited by 333
MICHELSON, D., BUITELAAR, J. K., DANCKAERTS, M., GILLBERG, C., SPENCER, T. J., ZUDDAS, A., FARIES, D. E., ZHANG, S., & BIEDERMAN, J. (2004) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000125089.35109.81 · Cited by 307
Cited by
Adult ADHD and comorbid disorders: clinical implications of a dimensional approach
Katzman, M. A., Bilkey, T. S., Chokka, P. R., Fallu, A., & Klassen, L. J. (2017) · BMC Psychiatry · doi:10.1186/s12888-017-1463-3 · Cited by 732
The Potential for Misuse and Abuse of Medications in ADHD: A Review
Clemow, D. B., & Walker, D. J. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.09.2801 · Cited by 198
Bond, D. J., Hadjipavlou, G., Lam, R. W., McIntyre, R. S., Beaulieu, S., Schaffer, A., & Weiss, M. (2012) · Annals of Clinical Psychiatry · doi:10.1177/104012371202400104 · Cited by 133
Katzman, M., & Sternat, T. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s111818 · Cited by 83
Upadhyaya, H. P., Desaiah, D., Schuh, K. J., Bymaster, F. P., Kallman, M. J., Clarke, D. O., Durell, T. M., Trzepacz, P. T., Calligaro, D. O., Nisenbaum, E. S., et al. (2013) · Psychopharmacology · doi:10.1007/s00213-013-2986-z · Cited by 82
“Previous reviews have demonstrated that atomoxetine is useful for patients at risk of substance abuse or who do not wish to take a controlled substance: atomoxetine is effective, has a favorable safety profile, and has a negligible risk of abuse or misuse (Garnock-Jones and Keating 2010; Simpson and Plosker 2004).”
Background
Metadata
- Authors
- Garnock-Jones, K. P., & Keating, G. M.
- Affiliations
- Wolters Kluwer Health (NZ)
- Corresponding author
- Garnock-Jones, Karly P.
- Venue
- CNS Drugs
- Published
- 2010-01
- Volume
- 24
- Issue
- 1
- Pages
- 85-88
- ISSN
- 1172-7047 (ISSN-L)
- OpenAlex
- W1965390021
- Cited by
- 32
- References
- 49
- Citations by year
- 2020: 3 · 2019: 2 · 2018: 1 · 2017: 2 · 2016: 5 · 2015: 1 · 2014: 3 · 2013: 5 · 2012: 4
- FWCI
- 2.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- CNS Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- atomoxetine, attention deficit hyperactivity disorder, norepinephrine reuptake inhibitors, methylphenidate, extended-release methylphenidate, amphetamine salts, drug efficacy, drug tolerability, abuse risk, children and adolescents
- MeSH terms
- Atomoxetine Hydrochloride, Adolescent, Attention Deficit Disorder with Hyperactivity, Child, Clinical Trials as Topic, Humans, Propylamines, Economics, Pharmaceutical, Adrenergic Uptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Spotlight on Atomoxetine in Attention-Deficit Hyperactivity Disorder in Children and Adolescents†. https://app.cochat.ai/papers/10.2165/11203670-000000000-00000
- The paper
- Garnock-Jones, K. P., & Keating, G. M. (2010). Spotlight on Atomoxetine in Attention-Deficit Hyperactivity Disorder in Children and Adolescents†. CNS Drugs. https://doi.org/10.2165/11203670-000000000-00000
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.